In the case of TOP2A, targeting of the C-terminus would enable selective targeting of TOP2A while avoiding TOP2B, which is associated with some treatment-induced adverse events (i.e. toxic effects of cancer therapy) (Murphy et al., 2017). The gene discussed is TOP2A; the disease is cancer.